Hospital
Punxsutawney Area Hospital INC
Punxsutawney Area Hospital INC was paid $2.82M by Medicaid between Jan 2018 and Dec 2024, across 157 billing codes. Its largest line is 99285, emergency room visit (most serious) — 25% of everything it billed.
33Billing provider infoPUNXSUTAWNEY AREA HOSPITAL INC
PUNXSUTAWNEY, PA 15767
PUNXSUTAWNEY, PA 15767
33aNPI1265449870assigned 08/03/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.82M
24GClaims135,430
24DCodes billed157
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#78 of 154
Median peer was paid$2.82M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 446 | $3K | |
| 2019 | 889 | $3K | |
| 2020 | 9,446 | $161K | |
| 2021 | 57,057 | $1.18M | |
| 2022 | 20,075 | $492K | |
| 2023 | 27,298 | $592K | |
| 2024incomplete | 20,219 | $394K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 25% | 6,252 | 5,940 | $703K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 5,185 | 4,962 | $476K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 5,119 | 4,912 | $342K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 4.6% | 3,138 | 1,960 | $130K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.9% | 1,302 | 1,247 | $109K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.5% | 2,235 | 2,128 | $70K |
| G0378 | Hospital observation service, per hour | 2.1% | 308 | 181 | $61K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.0% | 7,977 | 7,103 | $55K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 10,401 | 9,085 | $48K |
| 80050 | General health panel | 1.5% | 939 | 931 | $44K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 260 | 254 | $43K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.4% | 1,793 | 1,760 | $40K |
145 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 1,464 | $32K |
| 84450 | 1.1% | 5,944 | $31K | |
| 83615 | 1.1% | 5,751 | $31K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.1% | 894 | $31K |
| 93976 | 1.1% | 453 | $30K | |
| 82247 | 1.0% | 5,730 | $29K | |
| 83735 | <1% | 4,823 | $26K | |
| 82150 | <1% | 5,737 | $22K | |
| 84075 | <1% | 4,789 | $22K | |
| 80061 | Lipid panel | <1% | 1,571 | $21K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 258 | $20K |
| 80053 | Comprehensive metabolic panel | <1% | 1,596 | $16K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 41 | $16K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,057 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 785 | $15K |
| 83690 | <1% | 3,405 | $13K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 226 | $12K |
| 84484 | <1% | 1,842 | $12K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 196 | $12K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,733 | $11K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 58 | $11K |
| 84460 | <1% | 1,906 | $11K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,522 | $11K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 465 | $11K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 13 | $11K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 465 | $11K |
| 85730 | <1% | 1,688 | $9K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 238 | $9K |
| 87476 | <1% | 242 | $9K | |
| 82607 | <1% | 735 | $9K | |
| 82550 | <1% | 1,763 | $9K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 548 | $8K |
| 87040 | <1% | 441 | $8K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 239 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 944 | $6K |
| 84439 | <1% | 827 | $6K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 94 | $6K |
| 85610 | <1% | 2,098 | $6K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 246 | $5K |
| 82746 | <1% | 441 | $5K | |
| 81001 | <1% | 2,043 | $5K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 382 | $5K |
| 76536 | <1% | 92 | $4K | |
| 86780 | <1% | 272 | $4K | |
| 84145 | <1% | 198 | $4K | |
| 83605 | <1% | 626 | $4K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 75 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 81 | $3K |
| 82728 | <1% | 276 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 322 | $3K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 99 | $3K |
| 83540 | <1% | 320 | $3K | |
| 82043 | <1% | 308 | $2K | |
| 84702 | <1% | 152 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 49 | $2K |
| 73630 | <1% | 243 | $2K | |
| 81003 | <1% | 843 | $2K | |
| 97161 | <1% | 66 | $2K | |
| 83880 | <1% | 84 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 52 | $2K |
| 80076 | <1% | 247 | $2K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $2K |
| 73610 | <1% | 122 | $2K | |
| 81025 | <1% | 550 | $2K | |
| 85378 | <1% | 220 | $2K | |
| 87430 | <1% | 290 | $2K | |
| 87070 | <1% | 308 | $2K | |
| 86140 | <1% | 688 | $2K | |
| 84436 | <1% | 197 | $2K | |
| 87186 | <1% | 218 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 32 | $2K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 833 | $2K |
| 86850 | <1% | 213 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 41 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 226 | $2K |
| 87807 | <1% | 113 | $1K | |
| 87340 | <1% | 96 | $1K | |
| 80305 | <1% | 160 | $1K | |
| 86038 | <1% | 88 | $1K | |
| 84479 | <1% | 153 | $1K | |
| 85651 | <1% | 430 | $1K | |
| 72110 | <1% | 73 | $1K | |
| 83550 | <1% | 241 | $1K | |
| 73130 | <1% | 82 | $932.36 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 28 | $902.63 |
| 86901 | <1% | 214 | $784.74 | |
| 86900 | <1% | 214 | $779.20 | |
| 82565 | <1% | 151 | $767.79 | |
| 86803 | <1% | 38 | $731.01 | |
| 73030 | <1% | 65 | $722.38 | |
| 87088 | <1% | 117 | $717.79 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 32 | $690.50 |
| 82553 | <1% | 77 | $646.74 | |
| 87081 | <1% | 104 | $621.36 | |
| 82248 | <1% | 86 | $603.42 | |
| 94729 | <1% | 28 | $580.90 | |
| 87077 | <1% | 94 | $490.08 | |
| 84550 | <1% | 83 | $467.41 | |
| 84153 | <1% | 17 | $425.63 | |
| 86617 | <1% | 14 | $400.90 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,263 | $385.87 |
| 84403 | <1% | 14 | $385.29 | |
| 82951 | <1% | 27 | $369.26 | |
| 86762 | <1% | 17 | $365.21 | |
| 94727 | <1% | 26 | $360.65 | |
| 74019 | <1% | 24 | $341.82 | |
| 94060 | <1% | 42 | $324.36 | |
| 86787 | <1% | 15 | $270.17 | |
| 82784 | <1% | 14 | $238.82 | |
| 94664 | <1% | 27 | $227.63 | |
| 85027 | <1% | 32 | $214.27 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,796 | $212.56 |
| 83001 | <1% | 12 | $211.75 | |
| 84100 | <1% | 32 | $194.24 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 767 | $193.40 |
| 74018 | <1% | 14 | $181.38 | |
| 84165 | <1% | 12 | $163.36 | |
| 73560 | <1% | 16 | $161.88 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 45 | $145.47 |
| 85007 | <1% | 33 | $128.25 | |
| 73502 | <1% | 12 | $108.27 | |
| 86376 | <1% | 14 | $102.34 | |
| J3490 | Unclassified drugs | <1% | 223 | $99.50 |
| 84703 | <1% | 12 | $90.01 | |
| 86431 | <1% | 13 | $84.77 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 14 | $83.16 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,756 | $68.36 |
| 84520 | <1% | 14 | $62.94 | |
| 87205 | <1% | 13 | $33.53 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,194 | $28.80 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 935 | $8.19 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 583 | $6.48 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,312 | $5.93 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 987 | $1.48 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 901 | $0.60 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 31 | $0.00 |
| 3052F | 0% | 13 | $0.00 | |
| 88304 | 0% | 39 | $0.00 | |
| 3044F | 0% | 161 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 13 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 13 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 117 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 33 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 17 | $0.00 |
| 3051F | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSIMPSON, T. CLARK (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Punxsutawney Area Hospital INC | Punxsutawney, PA | $50K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.